STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference...

STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And
Conference Call
Company's Cash Position Improves

MONROVIA, Calif., July 14 /PRNewswire-FirstCall/ -- STAAR Surgical Company
(Nasdaq: STAA) today announced that it will release financial results for the
second quarter ended July 3, 2009 on Monday, August 3, 2009 before the market
opens. In addition, the Company today reported that cash and cash equivalents
and restricted cash as of July 3, 2009 were $13.1 million. This balance
includes the proceeds from the registered direct offering of common shares on
June 17, 2009 of $8.6 million. Cash and cash equivalents at the close of the
first quarter of 2009 on April 3 were $3.7 million.

"One of our 2009 key metrics is to focus on profitable growth and operational
efficiencies," said Barry G. Caldwell, President and CEO of STAAR Surgical.
"These efforts have resulted in an improved cash position even without
factoring in the positive impact of our financing on June 17th."

The Company will host a conference call and webcast on Monday, August 3, 2009
at 8:30 a.m. Eastern / 5:30 a.m.Pacific to discuss the Company's second
quarter results and current corporate developments. The dial-in number for
the conference call is 877-941-1848 for domestic participants and 480-629-9722
for international participants.

A taped replay of the conference call will also be available beginning
approximately one hour after the call's conclusion and will be available for
seven days. This replay can be accessed by dialing 800-406-7325 for domestic
callers and 303-590-3030 for international callers, both using passcode
4058578#. To access the live webcast of the call, go to STAAR Surgical's
website at www.staar.com. An archived webcast will also be available at
www.staar.com.

About STAAR Surgical
STAAR is a leader in the development, manufacture and marketing of minimally
invasive ophthalmic products employing proprietary technologies. STAAR's
products are used by ophthalmic surgeons and include the Visian ICL, a tiny,
flexible lens implanted to correct refractive errors, as well as innovative
products designed to improve patient outcomes for cataracts and glaucoma.
Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use
in treating myopia, has received CE Marking and is sold in more than 50
countries. More information is available at http://www.staar.com.

Safe Harbor
The data included in this release regarding STAAR's cash position as of the
end of the second fiscal quarter is preliminary and remains subject to review
by STAAR's independent registered public accountants in connection with the
preparation of STAAR's consolidated balance sheet as of July 3, 2009. Final
balance sheet data, which STAAR expects to report on August 3, 2009, may
differ.
CONTACT: Investors Media
EVC Group EVC Group
Doug Sherk Chris Gale
Mike Pollock 646-201-5431
415-896-5862

SOURCE STAAR Surgical Company

Investors, Doug Sherk or Mike Pollock, +1-415-896-5862, or Media, Chris Gale,
+1-646-201-5431; all of EVC Group for STAAR Surgical Company